Our data suggest that the introduction of TNF blockade into the clinical practice isassociated with increasing reports of leishmaniasis in patients with autoimmunerheumatic diseases who live in leishmaniasis-endemic areas of Europe. Here, TNF is linked to leishmaniasis.